ArticleResearch square2025
Serum Protein Dynamics in Early Pregnancy Loss Management: Findings from the PreFaiR Trial.
Article in Research square, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Medical management of early pregnancy loss (EPL) achieves ~90% efficacy with mifepristone-misoprostol combination versus ~70% with misoprostol alone, yet biomarkers predicting individual treatment response remain unknown. We performed proteomic analysis of serum samples from 59 participants in the PreFaiR trial, comparing pre- and post-treatment protein expression between responders and non-responders. Combination therapy showed 5 baseline predictors (LAP-TGF-β1, IL17RB, MYOC, CDH1, CD97) with higher expression in responders, while misoprostol monotherapy demonstrated 10 predictors with bidirectional patterns. Treatment-induced changes differed markedly: combination therapy showed significant alterations in 4 proteins, while misoprostol triggered changes in 30 proteins. TNNI3 emerged as a molecular efficiency marker, which showed almost no change between pre- and post-treatment levels in successful combination therapy but substantially declining post-treatment with misoprostol monotherapy. DPP7 showed opposite regulation between treatments among responders. These distinct molecular signatures provide evidence for treatment-specific mechanisms and offer potential biomarkers for personalized EPL management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.